GILD stock forecast, quote, news & analysis

Key Takeaways

• Gilead Sciences (GILD) shares trade near $150, up roughly 2% over the last 30 days and about 21% over the trailing three months.
• The advance reflects a market-leading HIV franchise built on Biktarvy, Descovy, and the twice-yearly injectable PrEP therapy Yeztugo.
• Management raised its full-year HIV sales growth outlook to a 9% to 10% range, with Yeztugo tracking toward roughly $1 billion in its first full year.
• Wall Street remains largely constructive, with a consensus Buy rating and an average price target in the high-$150s.
• No major loss-of-exclusivity events are expected until 2036, supporting the durability of the company's core franchise.

Current Market Snapshot

Gilead Sciences has delivered a steady climb over the past quarter even as the pace of gains moderated in recent weeks. Shares rose approximately 2% over the last 30 days and roughly 21% over the trailing three months, reflecting investor confidence in the company's HIV portfolio and its expanding pipeline rather than a single event-driven spike. The stock's relative strength has outpaced the broader healthcare sector during this stretch, and analyst commentary has largely reinforced a favorable view, with firms adjusting price targets higher while the consensus rating remains Buy.

Gilead Sciences (GILD) Business Overview and Competitive Position

Gilead Sciences is a Foster City, California-based biopharmaceutical company focused on antiviral therapies, oncology, and inflammation. Its dominant franchise is HIV, where Biktarvy remains the leading global treatment with more than half of U.S. market share and Descovy anchors daily oral pre-exposure prophylaxis (PrEP). The company has extended that leadership with Yeztugo (lenacapavir), a first-in-class, twice-yearly injectable PrEP option, and Bixlenvo, a once-daily single-tablet regimen for virally suppressed adults. Beyond virology, Gilead is building an oncology business around Trodelvy and cell therapies, while advancing a growing inflammation and immunology pipeline. Investors follow the stock for its dependable HIV cash flows, long-dated patent protection, dividend, and the optionality created by a diversified R&D effort.

Recent Developments Driving GILD

Several verified developments have shaped Gilead's recent trading. Second-quarter results showed HIV sales of $5.7 billion, up 12% year over year, with Biktarvy rising 7% to $3.8 billion, prompting management to lift full-year HIV growth guidance to a 9% to 10% range. The launch of Yeztugo has exceeded expectations, and the company has guided to approximately $1 billion in first full-year sales while its broader prevention portfolio surpassed $1 billion in quarterly revenue. The FDA approval and launch of Bixlenvo added another growth lever in the treatment-switch market.

On the access and pipeline front, Gilead expanded royalty-free voluntary licensing for once-yearly lenacapavir to 120 high-incidence countries and signed a regional agreement with the Pan American Health Organization to widen access across Latin America and the Caribbean. The company also opened a new research center at its Foster City headquarters to support oncology, inflammation, and data-science capabilities. In analyst coverage, HSBC raised its price target to $175 from $155 while maintaining a Buy rating, while RBC Capital held a more cautious stance with a Hold rating and a lower target, underscoring a range of views even as the broader consensus stays positive. Gilead is also advancing a once-weekly oral HIV combination with MRK.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this dedicated section. The featured robots vary in strategy, holding timeframe, and performance metrics, giving traders a way to compare different approaches rather than relying on a single model. Because selection is based on tracked performance and relevance, the page serves as a research starting point rather than a guaranteed signal. For those following GILD and other large-cap names, reviewing the Trending AI Robots section can offer an additional, data-driven perspective on momentum and market activity.

2026 Outlook and What Investors Should Watch

Looking ahead, investors are likely to monitor execution of the HIV portfolio and the cadence of pipeline milestones. Key catalysts include the potential approval of a weekly oral lenacapavir PrEP option in early 2027, data from the once-yearly lenacapavir program, and the anticipated launch of the anito-cel cell therapy for multiple myeloma. Multiple inflammation readouts are expected in the second half of 2026, and the company is advancing a once-weekly islatravir/lenacapavir combination with Merck. On the risk side, policy and pricing dynamics—including Medicare Part D redesign, Medicaid drug-pricing agreements, and Affordable Care Act-related changes—remain structural overhangs, while transaction-related charges from recent acquisitions have pressured near-term reported earnings. Elevated R&D spending and a premium valuation also warrant attention. These factors, rather than any single headline, are likely to define GILD's trajectory through 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations